CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Critical Bioanalytical Challenges of ADCs

Critical Bioanalytical Challenges of...

The Importance of Bioanalytical Method Validation

The Importance of Bioanalytical...

Korber Widens Its Werum PAS-X MES Service Partner Network

Korber Widens Its Werum PAS-X MES...

How New Regulations are Impacting the Life Science Sector

How New Regulations are Impacting the...

Significance of Bioanalytical Studies

Significance of Bioanalytical Studies

Invenio Genetics and Imagene Labs Announces Collaboration

Invenio Genetics and Imagene Labs...

Bioanalytical Testing Services and its Market

Bioanalytical Testing Services and...

Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Joins eGenesis as an independent director

Bradford Smith, Chief Financial...

Critical Bioanalytical Challenges of ADCs

Critical Bioanalytical Challenges of...

The Importance of Bioanalytical Method Validation

The Importance of Bioanalytical...

Korber Widens Its Werum PAS-X MES Service Partner Network

Korber Widens Its Werum PAS-X MES...

How New Regulations are Impacting the Life Science Sector

How New Regulations are Impacting the...

Significance of Bioanalytical Studies

Significance of Bioanalytical Studies

Invenio Genetics and Imagene Labs Announces Collaboration

Invenio Genetics and Imagene Labs...

Bioanalytical Testing Services and its Market

Bioanalytical Testing Services and...

Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Joins eGenesis as an independent director

Bradford Smith, Chief Financial...

The Future of Bioanalytical Outsourcing in the Pharma Industry

Life Sciences Review | Wednesday, August 18, 2021
Tweet

Today, pharma bioanalysis is outsourced and has broadened in scope, as large molecule drugs have become a significant part of many organizations' drug development pipelines.


FREMONT, CA: The biologics market is growing, resulting in increased demands on pharmaceutical and biotech firms to produce biologics more quickly. In the past, companies chose to manage drug development and production internally with scientists' in-house team. However, with heightened competition, restricted timeframes, and potential challenges, it has become vital for most pharmaceutical and biotech firms, regardless of their size, to consider using CROs as a remedy for more efficient development and production. Deciding to outsource can positively influence a study's outcome, especially when working with the right CRO.


Across pharma, there has been a small portion of bioanalytical work that was outsourced to a CRO. Back then, the usual outsourcing strategy was to outsource some late-stage clinical studies to CROs, while assistance for preclinical and early-stage clinical studies was retained within pharma. Over the years, streamlining of pipelines and mergers and acquisitions, the bioanalytical resources at both pharma and CROs have adjusted accordingly with a vast downsizing of internal bioanalytical resources at pharma and a rise in resources at the CROs.


Due to these alterations in pharma, there is a requirement to strategically move more bioanalytical work to CROs. With this change of work from pharma to CROs, talented bioanalytical scientists at pharma are also migrating to CROs, creating a great and sustainable partnership between pharma and CROs. Presently, bioanalytical practitioners at CROs are considered to be equal to their peers in the industry. Method development and other challenging bioanalytical work traditionally conducted in-house at pharma can now be reliably supported by CROs.


To accommodate the requirements of offering bioanalytical support for the present pharmaceutical drug discovery and development environment, both pharma and CROs are collaborating their resources strategically in a synergistic manner. It is never too early to think strategically about how and when to move the internal potentials to the external providers so that pharma resources can be better prepared for managing the next challenge on the horizon. Equally, CROs also want to find a new business model beyond just offering cost-saving for pharma, such as investing resources in new technologies and increasing innovative collaborations with pharma on resolving new bioanalytical hurdles.


Weekly Brief

loading
Top 10 Bioanalytical Service Companies in APAC - 2021
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/the-future-of-bioanalytical-outsourcing-in-the-pharma-industry-nwid-227.html